Results 201 to 210 of about 3,811,568 (245)
Some of the next articles are maybe not open access.
New developments in castrate‐resistant prostate cancer
BJU International, 2012Castrate‐resistant prostate cancer (CRPC) occurs when disease progresses in the presence of castrate levels of androgens and remains sensitive to further hormonal manipulation. For many years the treatment of CRPC was limited to the use of docetaxel for metastatic disease.
Shore, N., Mason, M., de Reijke, Th M.
openaire +2 more sources
Satraplatin for the Therapy of Castration-Resistant Prostate Cancer
Future Oncology, 2009While docetaxel-based chemotherapy improves survival in patients with castration-resistant prostate cancer, all of these patient's cancers will eventually progress and other active treatment agents are necessary. Satraplatin is a third-generation orally-available platinum analog that demonstrated a 33% reduction in the risk of progression in patients ...
Guru, Sonpavde, Cora N, Sternberg
openaire +2 more sources
Castration-resistance prostate cancer: what is in the pipeline?
Minerva Urology and Nephrology, 2018To evaluate the available evidence on the standard diagnosis and management of men with metastatic castration resistant prostate cancer (mCRPC), and providing the timely update on new pharmacological treatments.A systematic literature search from from January 2000 until March 2017 was performed by combining the following MESH terms: castrate resistant ...
DE Nunzio, Cosimo +4 more
openaire +3 more sources
Leading causes of castration-resistant prostate cancer
Expert Review of Anticancer Therapy, 2015Prostate cancer (PCa) is the second leading cause of cancer-related death in men. Androgen receptor has a key role in the initiation and progression of PCa. Currently, androgen deprivation therapy is the standard treatment for PCa patients due to its effective suppression of androgen receptor signaling.
Mingqian, Lu, Hongda, Lu, Qingzhi, Kong
openaire +2 more sources
Sequential Therapies in Castration-Resistant Prostate Cancer
Future Oncology, 2014153 ISSN 1479-6694 10.2217/FON.13.243 © 2014 Future Medicine Ltd Future Oncol. (2014) 10(2), 153–155 An unprecedented large number of agents capable of prolonging survival is presently available for patients with castrationresistant prostate cancer (CRPC) [1,2].
Carlo, Buonerba, Giuseppe, Di Lorenzo
openaire +2 more sources
Advances in the management of castration resistant prostate cancer
BMJ, 2016Docetaxel based chemotherapy showed survival benefit and emerged as the mainstay of treatment for castration resistant prostate cancer (CRPC) in 2004. However, therapeutic options have expanded rapidly since 2011. The spectrum of new agents is broad and includes drugs that target the androgen axis (enzalutamide, abiraterone), immunotherapy (sipuleucel ...
Chad R, Ritch, Michael S, Cookson
openaire +2 more sources
Emerging therapies in castrate-resistant prostate cancer
Current Opinion in Oncology, 2009Prostate cancer continues to represent a major health problem. It represents the most common cancer in US men, with an estimated 186 320 new cases diagnosed in 2008. It is the second leading cause of cancer death in men in the United States. Despite several attempts, the median survival for men with metastatic castrate-resistant prostate cancer is 1-2 ...
Kiran, Lassi, Nancy A, Dawson
openaire +2 more sources
The Molecular Evolution of Castration-resistant Prostate Cancer
European Urology Focus, 2016Androgen deprivation therapy (ADT) is the backbone of treatment for advanced prostate cancer. However, castration-resistant prostate cancer (CRPC) nearly invariably develops through a range of different molecular mechanisms accompanied by progression to a more aggressive phenotype.To understand the key molecular mechanisms leading to CRPC and the ...
Yvonne, Ceder +5 more
openaire +2 more sources
Management of nonmetastatic castration-resistant prostate cancer
Current Opinion in Supportive & Palliative Care, 2018Purpose of review The widespread use of prostate-specific antigen (PSA) resulted in stage migration of prostate cancer where androgen deprivation therapy (ADT) is administered for biochemical recurrence in patients following primary treatment.
Samer L, Traboulsi, Fred, Saad
openaire +2 more sources
Castration-Resistant Prostate Cancer: AUA Guideline
Journal of Urology, 2013This Guideline is intended to provide a rational basis for the management of patients with castration-resistant prostate cancer based on currently available published data.A systematic review and meta-analysis of the published literature was conducted using controlled vocabulary supplemented with keywords relating to the relevant concepts of prostate ...
Michael S, Cookson +11 more
openaire +2 more sources